Zachou et al. investigated whether autoantibodies against filamentous-actin and α-actinin could be used as predictors of response to treatment in patients with autoimmune hepatitis type 1 (AIH1). The researchers analyzed serum samples at baseline and after initiation of treatment in 86 patients with AIH1. Low levels of anti-α-actinin at baseline were found to be independent predictors of response, and the researchers conclude that serum levels of anti-α-actinin could be used to monitor treatment outcomes in patients with AIH1.
ORIGINAL RESEARCH PAPER
Zachou, K. et al. Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. Aliment. Pharmacol. Ther. doi:10.1111/j.1365-2036.2011.04908.x
Rights and permissions
About this article
Cite this article
New predictor of response to treatment in autoimmune hepatitis type 1. Nat Rev Gastroenterol Hepatol 9, 5 (2012). https://doi.org/10.1038/nrgastro.2011.230
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.230